72 Participants Needed

Brain Wave Monitoring for Traumatic Brain Injury

(INDICT Trial)

JA
KH
Overseen ByKarmen Herzig
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Cincinnati
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method for managing severe traumatic brain injuries by monitoring brain waves in real time. Researchers are testing whether using this brain wave data to guide treatment, known as the Treatment Algorithm, can control harmful brain activity and improve care. Participants may receive either this new experimental care or standard ICU care. Individuals who have undergone emergency brain surgery within 72 hours of a traumatic brain injury and meet other specific criteria may qualify for this trial. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this protocol is safe for traumatic brain injury patients?

Research has shown that using electrocorticography (ECoG) to monitor brain activity in people with traumatic brain injury (TBI) carries some risks. Studies indicate that over 25% of TBI patients might experience negative effects, such as seizures and blood vessel spasms. However, researchers are still studying the specific role of ECoG in guiding treatment.

Regarding the ketamine treatment in this trial, past studies have shown mixed results. Some research found that ketamine can lower pressure inside the skull, which benefits brain injury treatment. It was not linked to worse survival rates or increased disability, even in severely injured patients. However, concerns about raising this pressure have traditionally led to ketamine being avoided for TBI.

Since this study is in Phase 2, researchers are still assessing the safety of these treatments. This phase typically tests how well people tolerate the treatment and gathers more safety information. Prospective participants should know that while some evidence supports safety, more research is needed to confirm these findings.12345

Why are researchers excited about this trial?

Researchers are excited about the Brain Wave Monitoring for Traumatic Brain Injury trial because it explores a novel approach to managing traumatic brain injuries by using real-time brain wave data to guide treatment. Unlike standard ICU care, which follows general guidelines, this method uses a customized algorithm to monitor specific brain activity, known as spreading depolarizations (SDs), to adjust treatment. This targeted approach could lead to more precise interventions, potentially reducing secondary brain injuries and improving patient outcomes. By focusing on SD suppression through a tier-based protocol, this trial could offer a more dynamic and responsive treatment strategy compared to current practices.

What evidence suggests that this trial's treatments could be effective for traumatic brain injury?

Research has shown that monitoring brain activity, particularly patterns called spreading depolarizations (SDs), can aid in managing severe traumatic brain injury (TBI). In this trial, participants in the SD-Guided Care arm will have their ECoG data reviewed in real-time to guide treatment decisions. Previous studies using electrocorticography (ECoG) demonstrated its ability to predict recovery by detecting these patterns, assisting doctors in determining the best treatment.

Additionally, the SD-Guided Care arm will incorporate ketamine into the treatment algorithm. Studies have shown that ketamine can significantly reduce intracranial pressure in TBI patients. Although ketamine was once avoided due to safety concerns, recent research indicates it does not adversely affect the brain's pressure and blood flow.

Together, these methods offer a promising approach to managing severe TBI in the SD-Guided Care arm of this trial.56789

Are You a Good Fit for This Trial?

This trial is for individuals who need emergency surgery (craniotomy) to treat severe traumatic brain injury within 72 hours after the injury. It's not for those with non-survivable injuries, those who've had a certain type of skull surgery due to swelling, are in another TBI study, or are pregnant.

Inclusion Criteria

I need urgent brain surgery within 72 hours after a head injury.

Exclusion Criteria

I had surgery to relieve pressure inside my skull due to a severe brain injury.
Pregnancy
Co-enrollment in another therapeutic TBI trial
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants undergo intensive care with real-time electrocorticographic monitoring to guide therapy for spreading depolarization suppression

Up to 2 weeks
Continuous monitoring during intensive care

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
Periodic assessments

What Are the Treatments Tested in This Trial?

Interventions

  • Full-band Electrocorticography
  • Treatment Algorithm
Trial Overview The INDICT study tests if monitoring brain activity with electrocorticography can help guide intensive care treatments aimed at stopping spreading depolarizations—a harmful pattern seen after brain injuries—in patients post-surgery.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: SD-Guided CareExperimental Treatment2 Interventions
Group II: Standard ICU CareActive Control1 Intervention

Treatment Algorithm is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Ketalar for:
🇪🇺
Approved in European Union as Ketalar for:
🇨🇦
Approved in Canada as Ketalar for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Cincinnati

Lead Sponsor

Trials
442
Recruited
639,000+

University of New Mexico

Collaborator

Trials
393
Recruited
3,526,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Published Research Related to This Trial

The paper highlights the limitations of traditional Fast Fourier Transforms (FFTs) in analyzing EEG signals, particularly issues with resolution and leakage effects, and introduces an auto-regressive (AR) modeling approach to improve spectral estimation.
It also presents advanced algorithms, including adaptive AR parameter estimation and wavelet-based time-frequency representation, which are particularly effective for analyzing transient or rapidly changing neurological signals, as demonstrated through EEG data from animals experiencing hypoxic asphyxic brain injury.
Spectral analysis methods for neurological signals.Muthuswamy, J., Thakor, NV.[2019]
A new algorithm has been developed to effectively detect and track rhythmic patterns in EEG signals, which is crucial for monitoring brain activity in patients.
The algorithm successfully tracked the alpha rhythm in critically ill patients sedated with midazolam, indicating its potential utility in clinical settings for assessing brain function.
Tracking rhythm in long-term EEG recordings using empirical mode calculation.Lipping, T., Anier, A., Ratsep, I., et al.[2020]
Current management of traumatic brain injury (TBI) focuses on preventing and treating secondary brain damage rather than relying solely on pharmacological agents, which have shown limited success in clinical settings.
Recent studies indicate that using multimodal monitoring techniques to guide TBI treatment can lead to better patient outcomes by allowing for personalized care based on individual patient needs.
Physiological monitoring of the severe traumatic brain injury patient in the intensive care unit.Le Roux, P.[2022]

Citations

Noninvasive and reliable automated detection of spreading ...In this study, we establish the feasibility of automated SD detection through noninvasive scalp electroencephalography (EEG) for patients with severe TBI.
Continuous Electroencephalography after Moderate to ...Sleep Features on Continuous Electroencephalography Predict Rehabilitation Outcomes After Severe Traumatic Brain Injury. The Journal of head trauma ...
Full-Band Electrocorticography of Spreading ...Prolonged negative cortical DC shift of SD recorded by ECoG in patients with subarachnoid hemorrhage points to the inverse hemodynamic response ...
Predicting traumatic brain injury outcomes using a posterior ...A posterior dominant rhythm on electroencephalography is strongly associated with positive outcomes and to develop a novel machine learning–based model.
Prognostic Value of Electroencephalography in Critically Ill ...Still, the EEG features described and their potential additional value in outcome prediction after TBI merit further investigation. Open in ...
Detecting Cortical Spreading Depolarization with Full Band ...The primary outcome measure for patients with traumatic brain injury was functional outcome as expressed by Extended Glasgow Outcome Scale at ...
Electrocorticography in patients with severe traumatic brain ...The frequency of adverse outcomes in patients with severe traumatic brain injury (TBI) exceeds 25%. Epileptic seizures and vasospasm, in the absence of ...
Early EEG monitoring predicts clinical outcome in patients ...A total of hundred-seven patients with moderate to severe traumatic brain injury were included. Three patients were excluded due to lack of GOSE outcome scores ...
Noninvasive and reliable automated detection of spreading ...Increasing evidence shows that SDs are associated with poor clinical outcomes in traumatic brain injuries (TBIs), strokes, and hemorrhages4,5,6, ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security